+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are conducting a Phase 2 trial to compare TP-06 2.0% ophthalmic solution with a placebo vehicle in adults who have persistent corneal epithelial defects PCED that have not healed after at least 10 days of standard treatment. This trial aims to evaluate the safety and effectiveness of TP-06 in promoting corneal healing, improving visual acuity, and assessing changes in corneal thickness. Participants will be randomly assigned to receive either TP-06 2.0% or the vehicle four times daily for 8 weeks, alongside required background therapy. After the treatment phase, there will be a 2-week follow-up period to monitor healing and safety. The study is double-masked and involves multiple centers. During the study, participants will undergo assessments including evaluation of corneal healing through fluorescein staining, measurement of lesion size with imaging, and tests of visual acuity. Researchers will monitor the timing and extent of corneal healing and any safety concerns. The total participation time includes 8 weeks of treatment plus 2 weeks of follow-up.

Age: 18Years +All GendersPhase 2
14 locations
E

Actively Recruiting

Researchers are evaluating the Polaris System, a robotic device designed to assist surgeons in performing cataract surgery with improved precision and safety. This early feasibility, prospective, single-arm study focuses on patients aged 40 to 75 with uncomplicated, age-related cataracts. The goal is to assess the safety of the Polaris System by monitoring the rate of safety events over a 12-week period. Participants will undergo robot-assisted cataract surgery using the Polaris System. The procedure involves standard intraoperative eye preparation under general anesthesia, followed by docking the study eye to the device. The surgeon will use the Polaris System to perform initial surgical tasks, lens extraction, and intraocular lens implantation. After surgery, participants will have four scheduled follow-up visits over 90 days to monitor recovery and outcomes. During the study, participants will be evaluated through clinical examinations and safety assessments. Researchers will track surgical safety events up to 12 weeks after intervention to understand the devices safety profile. Participants must adhere to all study procedures, including medication regimens to prevent inflammation and infection, and attend scheduled follow-up visits. The total participation period includes the surgery and a 90-day follow-up phase.

Age: 40Years - 75YearsAll GendersPhase Not Applicable
1 location
R

Actively Recruiting

Researchers are evaluating two different management protocols for children aged 1 to 12 years with severe traumatic brain injury sTBI in Latin America. The study aims to determine if using a treatment approach guided by invasive intracranial pressure ICP monitoring leads to better outcomes compared to a protocol based solely on imaging and clinical exams. This trial builds on previous adult studies and addresses the unique needs of pediatric patients to improve care and guide global clinical practice. The study randomly assigns children to one of two treatment groups. One group receives care following a protocol that uses invasive ICP monitoring to guide management decisions, based on recommendations from the Brain Trauma Foundation Guidelines. The other group follows the CREVICE protocol, which manages sTBI using imaging and clinical examination without ICP monitoring. Both protocols focus on aggressive management of sTBI. The trial is conducted in eight pediatric intensive care units in Latin America, aiming to strengthen research skills among local pediatric intensivists. Participants will be closely monitored during their hospital stay, with the study measuring outcomes such as quality of life using the Pediatric Quality of Life Inventory PedsQL at three and six months, functional recovery with the Glasgow Outcome Scale - Extended Pediatric GOS-E Peds, mortality rates, brain-specific treatments, and length of stay in intensive care. Data will be collected for up to six months after injury to assess the effects of the two management strategies on recovery and complications.

Age: 1Year - 12YearsAll GendersPhase Not Applicable
11 locations
I

Actively Recruiting

Cancer is a major cause of illness and death among children, adolescents, and young adults CAYAs, particularly in low- and middle-income countries LMICs where access to timely diagnosis and treatment is often limited. This prospective, multicenter observational study follows CAYAs with cancer receiving routine care at participating hospitals in LMICs, aiming to better understand treatment outcomes and challenges faced by patients and families. Participants receive standard medical care as provided by their local hospitals without experimental treatments or changes to their treatment plans. The study observes a single group of patients over time to collect information from medical records and questionnaires focusing on access to care and social factors impacting treatment. The study covers a follow-up period extending up to 36 months after enrollment. During the study, researchers will gather data on clinical outcomes, treatment complications, interruptions, and social factors affecting care. Data collection includes medical record reviews and patient or family questionnaires. The study aims to provide valuable information to help improve cancer care and outcomes in resource-limited settings, with total participant engagement lasting up to three years.

Age: 0Years - 21YearsAll Genders
6 locations
D

Actively Recruiting

Researchers are evaluating an organ dysfunction score adapted specifically for pregnant and early postpartum patients up to 3 days after birth admitted to intensive care units ICU. This observational study aims to determine if this adjusted score, called SOFA-OBS, better predicts ICU mortality compared to the general SOFA score. The study also assesses whether a non-invasive pulse oximeter can effectively evaluate respiratory function instead of the standard arterial blood gas test, which is more painful and invasive. The study involves following pregnant and postpartum patients admitted to the ICU for at least 24 hours. Researchers will collect routine clinical data and laboratory results already used in ICU care, without requiring extra interventions. The SOFA-OBS score adjusts kidney function and blood pressure measurements to reflect the physiological changes during pregnancy and postpartum. It also replaces arterial blood gas oxygen measurements with pulse oximetry when blood gas analysis is unavailable. Data will be recorded daily during the ICU stay. Participants will be monitored for organ dysfunction and mortality outcomes during their ICU stay or up to 28 days after enrollment. Researchers will evaluate and compare the predictive ability of the SOFA-OBS and general SOFA scores for ICU mortality and sepsis-related death. Data quality will be carefully checked, and privacy will be protected by anonymizing patient information. The study is approved by ethical boards and requires informed consent from participants, with a planned enrollment of 130 patients.

Age: 18Years +FEMALE
18 locations
E

Actively Recruiting

This research evaluates a modified two-probe thermal ablation treatment using the IRIS device and assesses an AI-based Automated Visual Evaluation AVE triage algorithm among HPV-positive women in El Salvador. The main goal is to estimate the cure rates of cervical intraepithelial neoplasia grade 2 or worse CIN2 one year after treatment. The study also aims to compare the AVE algorithms diagnostic accuracy against traditional histopathology results. Participants eligible for ablation will receive thermal ablation with the IRIS device using a two-probe protocol. The treatment involves applying a short endocervical probe inside the cervical canal at 100C for 20 seconds, followed by overlapping applications of a flat ectocervical probe for the same duration until the entire affected area is treated. Women not eligible for ablation will be referred for standard care. A subset of participants will have additional follow-up visits at 6 weeks and 4-6 months to monitor safety and treatment effects. Digital cervical images will be collected for AVE algorithm analysis. Participants will undergo initial screening including HPV genotyping, colposcopy, biopsies, and endocervical curettage. Follow-up at one year will include repeat HPV testing and biopsies to assess cure rates. Safety and side effects will be monitored through questionnaires and additional biopsies in smaller groups. All samples will be analyzed by expert pathologists to establish diagnosis consensus. The study plans to enroll 5,000 women aged 30 to 49 who are HPV positive and non-pregnant, with an expected follow-up duration of one year for primary outcome assessment.

Age: 30Years - 49YearsFEMALEPhase Not Applicable
1 location
E

Actively Recruiting

Healthy Volunteer

Cervical cancer remains a major health challenge, especially in low- and middle-income countries where over 90% of cases occur. Current global strategies aim to eliminate cervical cancer by 2030, but many regions may not meet these goals until much later. This trial evaluates a new rapid and affordable screening method using the AmpFireae human papillomavirus HPV test combined with artificial intelligence-based imaging triage Automated Visual Evaluation, AVE to improve early detection and treatment in Honduras. The study involves testing 4,000 women with both self- and provider-collected samples using the modified AmpFireae platform to detect cervical precancer. Women who test positive or a small random sample of negatives will undergo further examination including visual inspection with acetic acid VIA, AVE, colposcopy, and biopsy. HPV-positive women may receive immediate ablation treatment if eligible. Additionally, 1,000 women will participate in a single-visit screening approach using self-sampling with follow-up testing one year later. The study also assesses the cost-effectiveness of the new approach compared to the current VIA strategy. Participants will complete questionnaires on acceptability and experience, and healthcare providers will be surveyed on the screening process. Follow-up visits at one year will include repeat HPV testing, AVE, and colposcopy for HPV-positive women. Outcomes measured include test accuracy, feasibility of same-day screening and treatment, and economic impact. Safety and quality of pathology review are monitored throughout. The total study duration for primary outcomes is two years.

Age: 30Years - 64YearsFEMALE
4 locations
E

Actively Recruiting

Researchers are evaluating the safety and feasibility of using Endo-Tek, a cultivated allogeneic corneal endothelial cell graft attached to a hydrogel substrate, to treat corneal endothelial cell dysfunction. This Phase 1 study aims to assess treatment-emergent and serious adverse events up to 24 weeks after transplantation. The study also investigates preliminary effectiveness by comparing vision quality, corneal thickness, and corneal cell density before and after surgery. Participants receive the Endo-Tek graft as a treatment during a surgical procedure. The study is designed as a single-group intervention where all enrolled participants undergo this treatment. After transplantation, participants are monitored for safety and changes in vision and corneal health over a 24-week period. Throughout the study, participants must attend follow-up visits to assess visual acuity, corneal thickness, and endothelial cell density, as well as monitor any adverse events related to the treatment. The total duration for safety assessment post-transplantation is 24 weeks, during which researchers gather data to evaluate the treatments safety and preliminary efficacy in this eye condition.

Age: 21Years +All GendersPhase 1
1 location
C

Actively Recruiting

Healthy Volunteer

Cervical cancer rates have dropped significantly in high-income countries due to prevention strategies, but low- and middle-income countries still bear most of the global burden, with about 85% of new cases and 90% of deaths. Screening is vital to reduce this burden, and the World Health Organization recommends human papillomavirus HPV testing as the best method. However, HPV testing can be costly and complex, often requiring women to return for results and treatment, which leads to many being lost to follow-up, especially in resource-limited settings. This study evaluates a same-day screen-and-treat approach using a low-cost HPV test called ScreenFire, compared to the standard two-visit approach, in El Salvador. Women will self-collect samples for HPV testing, and if needed, receive treatment on the same day. The study will enroll 1,000 women aged 30 to 59 years from remote areas over 10 to 15 weeks to see if the single-visit method reduces loss to follow-up. Participants will be followed for six months to measure how many return for care, with the main focus on the proportion lost to follow-up at six months. The study includes assessments of adherence to the screening program and the feasibility of local processing of the HPV test. The research team will monitor outcomes related to the effectiveness of the single-visit screening and treatment strategy, aiming to improve cervical cancer prevention in low-resource settings.

Age: 30Years - 59YearsFEMALEPhase Not Applicable
1 location
T

Actively Recruiting

This research aims to evaluate the safety and effectiveness of the Vizio Aqueous Microshunt, a medical device developed to treat refractory glaucoma by lowering intraocular pressure IOP to a level that may prevent further optic nerve damage without needing additional medications. Glaucoma is a major cause of irreversible blindness, and current drainage devices often still require medication. The Vizio device represents a next-generation technology developed to improve upon earlier devices with better healing and implantation techniques. Participants will receive the Vizio Aqueous Microshunt, which drains aqueous humor from the eyes anterior chamber to the eye surface, potentially improving IOP control predictability and reducing ocular surface symptoms common in glaucoma patients. The study is a single-arm clinical trial where participants will be implanted with the device and monitored. The trial builds on previous device versions and includes refined patient selection and physician training to enhance safety and efficacy. Throughout the 12-month study period, participants will undergo evaluations including applanation tonometry to measure IOP reduction and adverse event monitoring to assess safety. Additional assessments include responder rate and overall safety evaluations. Participants will have follow-up visits to monitor device performance and ocular health. The total study duration extends to primary completion by January 2028 and final completion by March 2029.

Age: 22Years - 85YearsAll GendersPhase Not Applicable
1 location

1-10 of 11

1